Davenport & CO LLC Ultragenyx Pharmaceutical Inc. Transaction History

Davenport & CO LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 18, 2022	BUY	$45.8 - $85.4 $20,884 - $38,942	456 Added 8.56%	5,782 $345,000
Q1 2022 May 02, 2022	BUY	$62.2 - $84.4 $70,597 - $95,794	1,135 Added 27.08%	5,326 $387,000
Q4 2021 Feb 10, 2022	BUY	$73.71 - $87.86 $4,127 - $4,920	56 Added 1.35%	4,191 $352,000
Q3 2021 Oct 14, 2021	BUY	$77.92 - $102.4 $68,803 - $90,419	883 Added 27.15%	4,135 $373,000
Q2 2021 Jul 28, 2021	BUY	$92.19 - $115.71 $299,801 - $376,288	3,252 New	3,252 $310,000

326

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.